Hofvind Solveig, Vacek Pamela M, Skelly Joan, Weaver Donald L, Geller Berta M
Department of Screening-Based Research, The Cancer Registry of Norway, Oslo, Norway.
J Natl Cancer Inst. 2008 Aug 6;100(15):1082-91. doi: 10.1093/jnci/djn224. Epub 2008 Jul 29.
Most screening mammography in the United States differs from that in countries with formal screening programs by having a shorter screening interval and interpretation by a single reader vs independent double reading. We examined how these differences affect early detection of breast cancer by comparing performance measures and histopathologic outcomes in women undergoing opportunistic screening in Vermont and organized screening in Norway.
We evaluated recall, screen detection, and interval cancer rates and prognostic tumor characteristics for women aged 50-69 years who underwent screening mammography in Vermont (n = 45 050) and in Norway (n = 194 430) from 1997 through 2003. Rates were directly adjusted for age by weighting the rates within 5-year age intervals to reflect the age distribution in the combined data and were compared using two-sided Z tests.
The age-adjusted recall rate was 9.8% in Vermont and 2.7% in Norway (P < .001). The age-adjusted screen detection rate per 1000 woman-years after 2 years of follow-up was 2.77 in Vermont and 2.57 in Norway (P = .12), whereas the interval cancer rate per 1000 woman-years was 1.24 and 0.86, respectively (P < .001). Larger proportions of invasive interval cancers in Vermont than in Norway were 15 mm or smaller (55.9% vs 38.2%, P < .001) and had no lymph node involvement (67.5% vs 57%, P = .01). The prognostic characteristics of all invasive cancers (screen-detected and interval cancer) were similar in Vermont and Norway.
Screening mammography detected cancer at about the same rate and at the same prognostic stage in Norway and Vermont, with a statistically significantly lower recall rate in Norway. The interval cancer rate was higher in Vermont than in Norway, but tumors that were diagnosed in the Vermont women tended to be at an earlier stage than those diagnosed in the Norwegian women.
美国的大多数乳腺筛查钼靶检查与实施正规筛查项目的国家不同,其筛查间隔较短,且由单一阅片者解读而非独立双阅片。我们通过比较佛蒙特州机会性筛查和挪威组织性筛查的女性的检查性能指标和组织病理学结果,研究了这些差异如何影响乳腺癌的早期检测。
我们评估了1997年至2003年期间在佛蒙特州(n = 45050)和挪威(n = 194430)接受乳腺筛查钼靶检查的50 - 69岁女性的召回率、筛查发现率和间期癌发生率以及肿瘤预后特征。通过对5岁年龄间隔内的发病率进行加权,以反映合并数据中的年龄分布,对发病率进行年龄直接调整,并使用双侧Z检验进行比较。
佛蒙特州年龄调整后的召回率为9.8%,挪威为2.7%(P <.001)。随访2年后,每1000妇女年的年龄调整后筛查发现率在佛蒙特州为2.77,在挪威为2.57(P =.12),而每1000妇女年的间期癌发生率分别为1.24和0.86(P <.001)。佛蒙特州侵袭性间期癌中15毫米或更小的比例高于挪威(55.9%对38.2%,P <.001),且无淋巴结受累的比例也更高(67.5%对57%,P =.01)。佛蒙特州和挪威所有侵袭性癌症(筛查发现的和间期癌)的预后特征相似。
在挪威和佛蒙特州,乳腺筛查钼靶检查发现癌症的速率和预后阶段大致相同,挪威的召回率在统计学上显著更低。佛蒙特州的间期癌发生率高于挪威,但佛蒙特州女性被诊断出的肿瘤往往比挪威女性被诊断出的肿瘤处于更早阶段。